HLA-B27 Testing and Genetic Markers

HLA-B27 testing identifies the presence of a specific human leukocyte antigen variant that carries significant diagnostic weight in rheumatology, particularly for a cluster of inflammatory diseases called spondyloarthropathies. This page covers what the test measures, how the laboratory process works, the clinical scenarios in which it is ordered, and the interpretive boundaries that govern its use. Understanding the role of HLA-B27 in rheumatologic workup requires separating what a genetic marker confirms from what it cannot rule out.

Definition and scope

HLA-B27 is an allele of the HLA-B gene located on chromosome 6, part of the major histocompatibility complex (MHC) class I region. The protein product presents intracellular peptide fragments to CD8+ T cells, a function central to immune surveillance. The clinical relevance of HLA-B27 lies in its strong statistical association with spondyloarthropathies — a family of inflammatory arthritides that includes ankylosing spondylitis, reactive arthritis, psoriatic arthritis, and enteropathic arthritis.

According to the National Institutes of Health Genetics and Rare Diseases Information Center (GARD), HLA-B27 is present in approximately 8% of the general US population of European descent, while prevalence rates differ substantially across ethnic groups — ranging from under 1% in sub-Saharan African populations to over 25% in certain Indigenous Arctic populations. Among individuals diagnosed with ankylosing spondylitis, HLA-B27 positivity rates reach 90–95% in most studied cohorts (National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIAMS).

The test sits within the broader category of genetic and immunogenetic markers used in rheumatology. For a broader view of how blood tests function in autoimmune disease workup, that context applies here as well. The rheumatology authority index provides orientation across the full diagnostic landscape.

How it works

HLA-B27 testing is performed on a peripheral blood sample. Two primary laboratory methodologies are used:

Flow cytometry — Fluorescent antibodies bind to HLA-B27 protein on the surface of lymphocytes. A flow cytometer quantifies the percentage of cells expressing the antigen. This method is fast, widely available, and suited for clinical laboratory settings.
Molecular (PCR-based) typing — Polymerase chain reaction techniques amplify specific HLA-B gene sequences to identify the allele at the DNA level. PCR-based methods distinguish between HLA-B27 subtypes (e.g., B27:05, B27:02), which matters in research and in cases where subtype-specific disease risk is under investigation.

The College of American Pathologists (CAP) accreditation standards govern laboratory performance for both methods, setting proficiency testing requirements for immunogenetics laboratories that report HLA results clinically. The American Society for Histocompatibility and Immunogenetics (ASHI) maintains separate accreditation standards for transplant and immunogenetics laboratories performing HLA typing (ASHI accreditation standards).

Results are reported as positive (HLA-B27 detected) or negative (not detected). Molecular subtyping produces an allele designation (e.g., B*27:05). No quantitative titer is produced — this is a presence/absence genetic test, not a serologic assay with fluctuating levels.

Common scenarios

HLA-B27 testing is ordered within defined clinical contexts, not as a general screening tool. The predominant ordering scenarios in rheumatology practice include:

Suspected ankylosing spondylitis or axial spondyloarthropathy — A patient presents with inflammatory back pain lasting more than 3 months, age of onset under 45, and morning stiffness exceeding 30 minutes. HLA-B27 positivity, combined with MRI findings of sacroiliitis, supports classification under the Assessment of SpondyloArthritis International Society (ASAS) axial spondyloarthritis criteria (ASAS criteria overview).
Workup for reactive arthritis — Following a documented genitourinary or gastrointestinal infection, HLA-B27 positivity is associated with increased risk of developing reactive arthritis and a more severe or prolonged course.
Uveitis of unclear etiology — Ophthalmology referrals for acute anterior uveitis may include HLA-B27 testing, since approximately 50% of cases of acute anterior uveitis are HLA-B27-positive (NIAMS).
Pediatric inflammatory arthritis evaluation — In juvenile idiopathic arthritis, HLA-B27 positivity in older male children correlates with enthesitis-related arthritis subtype and elevated risk of axial involvement.
Family history screening in research contexts — First-degree relatives of individuals with confirmed ankylosing spondylitis carry a higher a priori risk; HLA-B27 testing may be part of research protocols, though routine clinical screening in asymptomatic relatives is not standard practice.

The regulatory and clinical guideline landscape governing appropriate ordering is addressed more fully in the regulatory context for rheumatology, which covers payer coverage criteria and CMS coding considerations relevant to this class of genetic tests.

Decision boundaries

HLA-B27 is a risk-association marker, not a diagnostic test. Interpreting results requires applying firm boundaries:

Positive result does not confirm disease. Approximately 80% of HLA-B27-positive individuals in the general population never develop a spondyloarthropathy. A positive result elevates pre-test probability but requires corroborating clinical and imaging evidence to support diagnosis.

Negative result does not exclude spondyloarthropathy. Roughly 5–10% of ankylosing spondylitis cases are HLA-B27-negative. Non-radiographic axial spondyloarthropathy may also occur in HLA-B27-negative individuals who meet ASAS criteria on other grounds.

Ethnic background affects baseline prevalence. The positive predictive value of the test is meaningfully different in a patient of Northern European descent versus a patient of East Asian or sub-Saharan African descent, given the differing allele frequency baselines.

Subtypes carry variable risk profiles. Of the more than 160 known HLA-B27 subtypes identified through molecular typing, B27:05 (most common in European populations) and B27:02 (common in Mediterranean populations) are most strongly associated with spondyloarthropathy. B27:06 and B27:09 carry substantially lower disease association in population studies.

HLA-B27 is one component of a multi-modal diagnostic process that integrates clinical history, physical examination findings from a rheumatologic examination, inflammatory markers, and imaging. The test result alone does not trigger or preclude treatment decisions.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)